Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LYEL
STRONG SELLLyell Immunopharma, Inc. · Healthcare · United States · $309M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company developing novel cell therapies for cancer. It focuses on overcoming key challenges in cell therapy, such as T-cell exhaustion and poor trafficking, through innovative genetic and epigenetic reprogramming technologies. Lyell is a biotech innovator dedicated to enhancing the durability, potency, and localization of T-cells to improve cancer treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84.7M | 0.1M | 61.0K | 36.0K | -92.5% | 31.0K | 11.7K | 6.7M | 1268.4% |
| EPS | -14.80 | -18.70 | -23.26 | -12.91 | — | -13.21 | -7.64 | -7.86 | — |
| Shares | 12.5M | 12.7M | 14.7M | 21.3M | +70.3% | 23.3M | — | — | — |
| Debt | 67.7M | 63.2M | 59.0M | 51.0M | -9.0% | 48.9M | — | — | — |
| Equity | 833.3M | 655.0M | 382.8M | 248.2M | -33.2% | — | — | — | — |
| Op CF | -169.6M | -163.7M | -162.4M | -150.0M | — | -133.8M | — | — | — |
| Inv CF | -11.5M | 184.0M | 122.4M | 54.1M | — | — | — | — | — |
| Fin CF | 10.6M | 1.7M | 1.3M | 50.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LYEL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc.(you) | $309M | 2 | STRONG SELL |
| FHTX | Foghorn Therapeutics Inc. | $285M | 6 | STRONG SELL |
| OCGN | Ocugen, Inc. | $410M | 1 | STRONG SELL |
| UPB | Upstream Bio, Inc. | $349M | 8 | STRONG SELL |
| CMPX | Compass Therapeutics, Inc. | $373M | 7 | STRONG SELL |
| INDP | Indaptus Therapeutics, Inc. | $348M | 8 | STRONG SELL |
| LCTX | Lineage Cell Therapeutics, Inc. | $257M | 8 | STRONG SELL |
| NMRA | Neumora Therapeutics, Inc. | $276M | 10 | STRONG SELL |
| EVMN | Evommune, Inc. | $409M | 7 | STRONG SELL |
| EDIT | Editas Medicine, Inc. | $399M | 8 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%